Support for you and appropriate patients with overt HE

The resources below include information that may help when prescribing XIFAXAN, insurance requirements, and videos about OHE. You’ll also find materials to share with appropriate patients with OHE. These resources may help you get appropriate patients on XIFAXAN and help them reach your goals for OHE management.

AASLD/EASL 2014 Guideline Flashcard

Quickly review some of the recommendations for adult patients with overt HE.

XIFAXAN Dosing Flashcard thumbnail
XIFAXAN Dosing Flashcard

A summary of dosing information for prescribing XIFAXAN.

Considerations for PAs Handout thumbnail
Considerations for PAs Handout

Provides direction for submitting a PA for XIFAXAN when needed.

Sample Letter of Medical Necessity thumbnail
Sample Letter of Medical Necessity

A standard form for a patient‐specific letter of medical necessity to explain your clinical decision-making in choosing a therapy.

Tier Exemption Request thumbnail
Tier Exemption Request

A Tier Exemption Request to reduce the cost-share of a medication. Follows submission of a PA or Utilization Management request.

OHE, overt hepatic encephalopathy

AASLD, American Association for the Study of Liver Diseases

EASL, European Association for the Study of the Liver

PA, prior authorization

Wrestling the Monster

Study the face of HE in 4 patients and their caregivers as they describe the toll HE takes on them and their families.

HE = hepatic encephalopathy

XIFAXAN OHE Flashcard Kit thumbnail
XIFAXAN OHE Flashcard Kit

A brief overview about managing OHE with XIFAXAN, including dosing and savings program details.

HE Symptoms Checklist thumbnail
HE Symptoms Checklist

A handy tool to help patients and caregivers recognize the mental and physical symptoms of HE.

Extra Help/LIS Brochure thumbnail
Low-income Subsidy Brochure

Learn about Extra Help/LIS program benefits. Identify the two ways patients can receive Extra Help/LIS benefits. Discover how you can help patients apply for Extra Help/LIS benefits.

Copay card thumbnail

Instant Savings Card

Available for eligible,* commercially insured patients.

HE, hepatic encephalopathy

LIS, Low-income subsidy

*Patient is not eligible if he/she participates in or seeks reimbursement or submits a claim for reimbursement to any federal or state healthcare program with prescription drug coverage, such as Medicaid, Medicare, Medigap, VA, DOD, TRICARE, or any similar federal or state health care program (each a Government Program), or where prohibited by law. Patient must be enrolled in, and must seek reimbursement from or submit a claim for reimbursement to, a commercial insurance plan. Offer excludes full cash-paying patients. Maximum benefits and other restrictions apply. Visit or call 1-866-XIFAXAN for full eligibility criteria, terms and conditions.

Time to Take Action Tool
Time to Take Action

Take on this interactive challenge and determine what you would do for these patients.


XIFAXAN® (rifaximin) 550 mg tablets are indicated for the reduction in risk of overt hepatic encephalopathy (HE) recurrence in adults and for the treatment of irritable bowel syndrome with diarrhea (IBS-D) in adults.

  • XIFAXAN is contraindicated in patients with a hypersensitivity to rifaximin, rifamycin antimicrobial agents, or any of the components in XIFAXAN. Hypersensitivity reactions have included exfoliative dermatitis, angioneurotic edema, and anaphylaxis.
  • Clostridium difficile-associated diarrhea (CDAD) has been reported with use of nearly all antibacterial agents, including XIFAXAN, and may range in severity from mild diarrhea to fatal colitis. If CDAD is suspected or confirmed, ongoing antibiotic use not directed against C. difficile may need to be discontinued.